Board of Directors
With a career spanning nearly 40 years in lasers, optics, microscopy, life sciences and healthcare, David studied engineering at University and gained his PhD in the application of high power lasers for materials processing. Following several management appointments in the laser industry, he joined Leica Microsystems where he ultimately became CEO for 5 years. Earlier at Leica Microsystems he led their confocal laser microscopy business. David was a VP in Danaher, responsible for Life Science and Diagnostics, and more recently was CEO at Tecan for 7 years, a market leading Swiss listed company developing automated robotic workstations and imaging systems for Life Science and Diagnostic applications.
Today, David is Chairman of Sebia Diagnostics (FR); BBI Solutions (UK); Rayner Intra-Ocular Lenses (UK); a member of the Novo Advisory Group of Novo Holdings (DK) and an adviser to RealWorld One (DE).
Renato Giacobbo Scavo
A degree in Electronic Engineering at University of Rome and an MBA at HEC School of Business, he has been working for over 20 years in Venture Capital and Private Equity industries. Manager at Bain & Company focused on innovation, Investment Director at Jupiter Finance and then since 2007 serial entrepreneur and investor with several successful exits in high-tech industries.
Early founder and Board Member of CrestOptics since 2013; CEO of the company since 2020
Rodrigo is a Senior Global Executive in the Medical Device Industry with over 30 years of experience in some of the most important Medical Devices companies.
He started his career at Procter & Gamble and in 1987 he joined Johnson&Johnson where he covered several roles including: President Worldwide DePuy Mitek (2001-2003) and President Worldwide Ethicon (2004-2005).
From 2013 to 2019 Mr. Bianchi was part of Smith&Nephew where he served as President International Markets. He holds a bachelor’s degree in Economics from Rome University and a Master in Business Administration from Luiss Business School in Rome.
Alessandro Maria Cremona
Alessandro has over twenty-three of experience in the banking industry. He was Nomura Italia SpA CEO from 1996 to 2010, heading also the Investment Banking activity. Currently, he is Chairman of Goldmann & Partners Società Benefit, a design company operating in bioclimatic/biophilic architecture/ engineering and consultancy to implement sustainable and circular processes. Goldmann & Partners is B Corp certified. He is also a non-executive director of SoGeMi, a company managing wholesale food markets of Milan (owned by Milan Municipality). Since October 2021, Alessandro has been CEO of D-TAILS, a spin-off of CrestOptics dedicated to diagnostics. He holds a degree in Physics (Milano University) and spent more than one year at the University Of Oregon (USA). He also got an MBA with honour from SDA Bocconi Milano.
Lauren joined Apposite in 2018 from Jefferies’ Healthcare Investment Banking team. At Apposite she is a member of the investment team and works closely with management teams on business building through strategy, business development, M&A and debt and equity financing. In particular she is or has been involved in Apposite’s investments in 1MED, Emblation, Mirada Medical and MC Care Holdings. During her time at Jefferies, she advised on buy-side and sell-side mandates, product licensing and public capital raises across a variety of healthcare sub-sectors including dental, nanomedicine, biopharma, children’s services and pharma services. Lauren has a BA in Psychology and Philosophy from Oxford University.
Luca is the Managing Director at XYence Capital, European life sciences investment firm based in Milan. With a successful track record of over two decades in the sector, XYence has created a platform that turns new science into new products, improving outcomes for patients. XYence’s aim is to help create value for innovators, investors and health care systems.
Prior to XYence, Luca worked for 9 years at Rocket Internet, building and investing in businesses in the tech and e-commerce space.
Luca holds a MBA from Harvard Business School.
David has over 30 years of experience in private equity and investment banking. He has advised on a wide range of companies and at Apposite, he serves or has served on the Boards of MC Care Holdings, NIMGenetics, Swanton Care, CancerPartnersUK, Ulthera, Zonare and Xthetix. Prior to co-founding Apposite in 2006, David worked on a number of large leveraged buy-outs with Nomura’s Principal Finance Group. He then founded and headed Nomura International’s healthcare investment and corporate finance groups. David has been the CEO of a number of companies, including CLF Municipal Bank, an authorised bank. David is very involved in the UK healthcare industry, having served as a member of the UK government’s Health Reform Group looking at reforms to the provision of healthcare to NHS patients and on the London Health Commission. David has a degree in Chemistry from Oxford University.
Thirty-five years of experience in system design and field tests in Infrared technology and imaging systems. For the last 25 years, he has been on the BOD of several companies manufacturing or selling Electro-Optics products. He played a key role in establishing and guiding research and development projects carried on within the Joint Lab collaboration between CrestOptics and IIT (Italian Institute of Technology). Since October 2021 he is the Scientific Director of D-TAILS, spinoff of CrestOptics dedicated to diagnostics.